BI 1910
Alternative Names: BI-1910Latest Information Update: 05 Feb 2025
At a glance
- Originator BioInvent International
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; Type II tumour necrosis factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 08 Jan 2025 Efficacy and adverse event data from a phase I/IIa trial in Solid tumours released by BioInvent International
- 31 Dec 2024 BioInvent International and Merck Sharp & Dohme agree to co-develop BI 1910 for Solid tumours, prior to December 2024
- 05 Dec 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in Europe, USA (Parenteral)